The odd gap in the middle of diabetes care

Here is something most people with type 2 diabetes never get told. Two of the most important drug classes of the last decade, the SGLT2 inhibitors and the GLP-1 receptor agonists, are routinely prescribed together. Guidelines from the American Diabetes Association, the European Society of Cardiology and Diabetes Canada all make room for adding one on top of the other in higher risk patients.

And yet, as of this paper, nobody had run a randomised controlled trial that compared the pair against either drug alone for mortality and cardiovascular outcomes.

Read that twice. The combination is in the guidelines. The head to head trial does not exist.

That is not a scandal. It is how medicine often moves. Each drug class earned its place separately in huge outcome trials, and doctors started stacking them because the logic held up. What was missing was a proper look at what actually happens to people on both. That is the hole Aftab Ahmad and Hani Sabbour set out to fill, working from Abu Dhabi, with a 2024 meta-analysis of real-world data.

What each drug actually does

Before getting into numbers, it helps to know why anyone thought these two would pair well. They attack the problem from completely different ends.

SGLT2 inhibitors (the "flozins": dapagliflozin, empagliflozin, canagliflozin) work in the kidney. Normally your kidneys filter sugar out of your blood and then pull almost all of it back in. SGLT2 is the transporter that does the pulling back. Block it, and a chunk of that sugar leaves in your urine instead. You also lose some sodium and water along with it, which is part of why these drugs lower blood pressure.

GLP-1 receptor agonists (liraglutide, dulaglutide, semaglutide and friends) are peptide drugs that mimic a gut hormone. They push the pancreas to release insulin when glucose is high, slow down how fast your stomach empties, and act on appetite centres in the brain so you feel full sooner. The upshot is lower glucose and, for many people, less food eaten.

One drug makes you lose calories through the kidney. The other makes you want fewer calories to begin with. One lowers blood pressure mostly through salt and water. The other seems to protect blood vessels through anti-inflammatory effects. There is very little overlap in how they work, which is exactly the argument for combining them.

The detail that makes the pairing smarter than it looks

There is a quiet problem with SGLT2 inhibitors alone that the paper points out. When you start losing calories through your urine, your body notices, and appetite tends to creep up. People often lose less weight than the maths predicts because they eat a bit more to make up for it.

Now think about what a GLP-1 drug does. It turns appetite down.

So one drug creates a calorie deficit, and the body's natural response to that deficit gets blunted by the other. That is not marketing copy. It is a genuinely neat bit of physiology, and it is the kind of thing worth understanding before anyone hands you a prescription for both.

There is a kidney angle too. SGLT2 inhibitors need working kidneys to do their glucose-lowering job. The paper notes that once kidney function drops below an eGFR of 30, the HbA1c effect of an SGLT2 inhibitor becomes negligible. GLP-1 drugs lower glucose independent of kidney function. So as kidneys decline, the second drug keeps doing the work the first one can no longer do.

Why real-world data, and why that matters

Randomised trials are the gold standard because they strip out bias. You flip a coin, one group gets the drug, one does not, and the comparison is clean.

But trials also recruit carefully. They exclude people who are too sick, too old, on too many other medications, or unlikely to show up to appointments. The people in trials are often not the people in the waiting room.

Real-world studies look at what happens to ordinary patients being treated in ordinary clinics. They are messier. They are also closer to your actual life. The authors made a deliberate choice to only look at this kind of evidence, because, as they put it, results in the real world can differ significantly from results in trials.

That choice cuts both ways, and later in this series I will be blunt about the costs. For now, understand the trade: less control, more realism.

What the series will cover

Over the next seven parts we will walk through what this paper found and what it did not.

We will look at how 1,445 search results became 13 included studies. We will get into the headline mortality number, which is large enough that it deserves both excitement and suspicion. We will look at blood sugar, weight and blood pressure, whether the order you start the drugs in matters, and what happened to kidneys. Then one part will do nothing but pick holes, because a series that only reports good news is a brochure. We finish with the most practical question of all: why many people who might benefit are not being offered the combination.

If you are on one of these drugs now, or you are about to be, you will come out of this knowing more about the evidence than most people who prescribe it casually.

This series discusses a peer-reviewed meta-analysis of observational studies. Nothing here is medical advice. Do not start, stop or combine prescription medications without your doctor.